REPL
Replimune Group (REPL)
$86
About Replimune Group (REPL)
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
Details
Daily high
--
Daily low
--
Price at open
--
52 Week High
$13.86
52 Week Low
$1.50
Market cap
994.0M
Dividend yield
0.00%
Volume
19,749
Avg. volume
7.0M
P/E ratio
-3.37
Replimune Group News
Details
Daily high
--
Daily low
--
Price at open
--
52 Week High
$13.86
52 Week Low
$1.50
Market cap
994.0M
Dividend yield
0.00%
Volume
19,749
Avg. volume
7.0M
P/E ratio
-3.37